Loading
Atherosclerosis and Cardiovascular Diseases · Journal article
Journal of Clinical Medicine · July 28, 2026
A consensus or society position rather than new primary data.
This narrative review synthesizes evidence that Lp(a) is a genetically determined, clinically relevant contributor to residual cardiovascular risk through pro-atherogenic, pro-inflammatory, pro-thrombotic, and pro-calcific mechanisms in coronary artery disease and aortic valve disease. Elevated Lp(a) has been associated with worse outcomes after PCI (recurrent ischemic events, repeat revascularization, in-stent restenosis) independent of LDL control, and emerging targeted therapies show substantial circulating level reductions, yet outcome trials are needed to confirm clinical benefit.
Narrative review. Patients with coronary artery disease undergoing percutaneous coronary intervention and patients with aortic valve disease undergoing or considering transcatheter aortic valve implantation.
Elevated Lp(a) in PCI patients associated with worse long-term outcomes including recurrent ischemic events, repeat revascularization, and in-stent restenosis, even with controlled LDL cholesterol Experimental, genetic, and clinical data support role for Lp(a) in initiation and progression of calcific aortic stenosis Emerging targeted therapies achieving substantial reductions in circulating Lp(a) levels
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Interventional cardiologists should recognize elevated Lp(a) as a meaningful biomarker associated with worse outcomes after PCI independent of LDL control, and should be aware of emerging targeted therapies, though definitive outcome trial evidence is not yet available to guide treatment decisions in routine practice.
Narrative review synthesizing evidence on Lp(a) pathophysiology and clinical role in coronary and aortic valve disease, with guidance on emerging therapies, but lacking new primary trial data or definitive outcome evidence.
As stated by the source record.
Interventional cardiologists should recognize elevated Lp(a) as a meaningful biomarker associated with worse outcomes after PCI independent of LDL control, and should be aware of emerging targeted therapies, though definitive outcome trial evidence is not yet available to guide treatment decisions in routine practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Lipoprotein(a) (Lp(a)) is increasingly recognized as a genetically determined and clinically relevant contributor to residual cardiovascular risk. Through pro-atherogenic, pro-inflammatory, pro-thrombotic, and pro-calcific mechanisms, Lp(a) appears to play a significant role in both coronary artery disease and aortic valve disease. In patients undergoing percutaneous coronary intervention, elevated Lp(a) has been associated with worse long-term outcomes, including recurrent ischemic events, repeat revascularization, and in-stent restenosis, even in the setting of controlled low-density lipoprotein cholesterol. In parallel, experimental, genetic, and clinical data support a role for Lp(a) in the initiation and progression of calcific aortic stenosis, while its prognostic significance after transcatheter aortic valve interventions remains less clearly defined. Current guidelines now recognize Lp(a) as a relevant risk-enhancing factor, and emerging targeted therapies are achieving substantial reductions in circulating levels. Overall, Lp(a) should be regarded as both a meaningful biomarker and a promising therapeutic target, although ongoing outcome trials are needed to determine whether selective Lp(a) lowering translates into clinical benefit across interventional cardiovascular settings. The aim of this narrative review is to provide a single, comprehensive account of lipoprotein(a) [Lp(a)] in interventional cardiology, following this lipoprotein from its biology and pathophysiology through to its clinical impact and to the therapies that are now reaching the clinic, with a specific focus on the two most frequent catheter-based procedures in which it may carry prognostic weight: percutaneous coronary intervention (PCI) and transcatheter aortic valve implantation (TAVI). PCI and TAVI are deliberately addressed within the same review since they share a common upstream biology: Lp(a) contributes both to the atherosclerotic process that underlies coronary disease and to the calcific process that underlies aortic valve disease, and the corresponding patient populations overlap considerably in everyday interventional practice. Covering them together offers the interventional cardiologist a single, practical reference on how a patient with elevated Lp(a) may be approached in both scenarios.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.